Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J. et al, (2018), Lancet Oncol, 19, 1530 - 1542
Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands
LU X. et al, (2018), Nature Communications
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Corrie PG. et al, (2018), Ann Oncol, 29 Suppl 8
Comparison of the measurement properties of paper and electronic version of HM-PRO, a new patient-reported outcome measure for use in patients with haematological malignancies: an equivalence study
Goswami P. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S138 - S139
OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer.
Blagden S. et al, (2018), Ann Oncol, 29 Suppl 8, viii333 - viii334
Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors.
Middleton MR. et al, (2018), Ann Oncol, 29 Suppl 8
Systematic review of patient-reported outcome measures used in randomised clinical trials testing checkpoint inhibitor immunotherapy for cancer
Peters M. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S117 - S118
Publisher Correction: Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.
Farmery JHR. et al, (2018), Scientific reports, 8, 13376 - 13376
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
Collins GP. et al, (2018), Leuk Lymphoma, 59, 2113 - 2120
Anti-tumor activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
BLAGDEN S. et al, (2018), British Journal of Cancer
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP. et al, (2018), British journal of haematology
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W. et al, (2018), J Clin Oncol, 36, 2395 - 2404
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC. et al, (2018), The Lancet. Oncology, 19, 1027 - 1039
Single Cell Analysis Resolves Genetic and Transcriptional Heterogeneity in Myeloproliferative Neoplasms
Rodriguez-Meira A. et al, (2018), Experimental Hematology, 64
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
Lipplaa A. et al, (2018), British Journal of Cancer
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer
Lord SR. et al, (2018), Cell Metabolism